Complete AV Block in Vaccinated COVID-19 Patient

 An 84-year-old male with a history of coronary artery disease, hypertension, and hyperlipidemia presented to an urgent care in with body aches, malaise, fatigue, and dyspnea for three days - six months after receiving second doze of Pfizer vaccine. No other infectious symptoms were endorsed. He denied any symptoms of lightheadedness, dizziness, palpitations, orthopnea, and chest pain.At the outside facility, he was found to be bradycardic with a complete AV block. Total of atropine 1.0 mg was administered at that encounter. Afterwards, the patient went into a supraventricular tachycardia briefly with spontaneous return to a complete AV block. He was placed on transcutaneous pacing. His previously known heart rate ranged between 77 and 99 and a visit to his cardiologist a week prior reveled no abnormalities. Prior PR interval was 128. He had no history of tobacco, alcohol, or drug use. A possible culprit home medication was atenolol 50 mg daily which he reported taking as instructed. No other pertinent or new medications were noted in the patient’s history.


Underlying EKG without pacing showed an atrial rate of 128 bpm and a ventricular rate of 48 bpm. Chest X-ray on admission showed pulmonary infiltrates without cardiomegaly

The patient was started on a low-dose dopamine infusion at 10 mcg/kg/min and dexamethasone 6 mg IV QD. Infectious disease team was consulted, and remdesivir was started based on a multidisciplinary team approach. Blood pressure remained between 140/76 and 162/62. The patient remained awake and comfortable. The patient was offered both cardiac catheterization and permanent pacemaker placement; however, after an extensive discussion with the patient and his son, the patient refused all invasive therapeutic intervention. The patient was discontinued off the dopamine infusion as well as transcutaneous pacing; however, he was continued on methylprednisolone and remdesivir. On posthospitalization day 6, his symptoms at onset had grossly improved, and given his aversion to testing, no follow-up imaging was conducted. He was discharged safely still in AV block with home oxygen.

READ MORE


REFERENCE

Lee K, Rahimi O, Gupta N, Ahsan C. Complete AV Block in Vaccinated COVID-19 Patient. Case Reports in Cardiology. 2022 Mar 30;2022.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more